| Current Medical Articles |
|---|
 |
The Motley Fool
May 12, 2008
Brian Orelli |
Merging Mylan Meanders Through 2008 In the larger-is-better world of generic-drug makers, it's kind of surprising that investors haven't yet gotten behind the Mylan/Merck KGaA deal.   |
The Motley Fool
May 12, 2008
Brian Orelli |
Lowering the Barr Barr Pharmaceuticals disappoints by lowering expectations. |
The Motley Fool
May 12, 2008
Brian Lawler |
Hep C Drugs Slug It Out Does Vertex's telaprevir really trump Schering's boceprevir? |
Popular Mechanics
May 8, 2008
Chris Ladd |
Autonomous 3D Robot Doc Gets X-Ray Powers With DIY A.I. Looks like the robotic uprising could be headed for the OR after all: Bots can now see through your flesh in three dimensions and direct a mechanical arm to perform a biopsy. |
BusinessWeek
May 8, 2008
Arlene Weintraub |
Big Drug R&D on Campus With pipelines drying up, drugmakers are enlisting universities to help create new treatments. |
BusinessWeek
May 8, 2008
Arlene Weintraub |
The Doctor vs. Device Makers Dr. Charles Rosen is on a mission to end the conflicts of interest between manufacturers and physicians. |
Chemistry World
May 8, 2008
Hepeng Jia |
China to fast track pioneering drugs China is to speed up the approval of groundbreaking new drugs in an effort to encourage innovation in its pharmaceutical sector, a State Food and Drug Administration (SFDA) official has revealed. |
The Motley Fool
May 7, 2008
Brian Orelli |
Black Onyx, but Not for Long Onyx posts a stellar quarter, but earnings for the pharmaceuticals company are headed in the other direction for the rest of the year. |
The Motley Fool
May 7, 2008
Brian Orelli |
Teva's on a Tear The generic-drug maker can't be stopped. |
The Motley Fool
May 7, 2008
Brian Lawler |
Cephalon's Long Shot Falls Short An FDA advisory panel brings bad news for the company. |
The Motley Fool
May 6, 2008
Brian Orelli |
A Sign of the Pharma Times Merck is the latest big pharma cutting jobs to improve its bottom line. |
The Motley Fool
May 6, 2008
Brian Lawler |
MannKind Moves Ahead The pharmaceutical awaits pivotal data on its lead drug Technosphere. |
The Motley Fool
May 6, 2008
Steven Renaldi |
McKesson Garners Generic Growth New products offer the generic-drug distributor profit potential in a competitive industry. |
Information Today
May 5, 2008 |
Premerus Introduces Medical Misdiagnosis Portal Premerus provides a platform for consumers to read and post their own experiences to share insights about the impact of diagnostic errors. |
The Motley Fool
May 5, 2008
Brian Orelli |
A Short Wait for Discovery Labs? The company gets a third letter about Surfaxin, but should be able to satisfy the FDA soon. |
The Motley Fool
May 5, 2008
Brian Lawler |
Good News for Abuse-Resistant Drugs Drug developers working on harder-to-abuse pain remedies, including Pain Therapeutics, King Pharmaceuticals, and Alpharma, got a guarded thumbs-up from the FDA last week. |
The Motley Fool
May 2, 2008
Brian Orelli |
Sepracor Diversifies to Sleep Better With its two top drugs in decline, diversification was the only answer for Sepracor. |
The Motley Fool
May 2, 2008
Steven Renaldi |
Cardinal Health Gets Its Nest in Order Share price rises as investors hope the company is beginning to put some of its troubles behind it. |
BusinessWeek
May 1, 2008
Bruce Einhorn |
Made in China: MRI Machines Medical device makers are stepping up manufacturing on the mainland, raising safety concerns. |
The Motley Fool
May 1, 2008
Brian Lawler |
Soliris Brightens Alexion's Quarter Alexion Pharmaceuticals' lone drug posts gargantuan growth. |
The Motley Fool
May 1, 2008
Brian Lawler |
Glaxo's Global Growth Gambit The pharmaceutical's new CEO has changes in mind. |
Chemistry World
May 2008
Derek Lowe |
In the pipeline The controversy over cholesterol drug Vytorin has been going on for months. Surveying the wreckage, my first thought is: what a terrible shame the whole affair is. |
The Motley Fool
April 30, 2008
Brian Lawler |
Pfizer Protects Profitable Patent The courts uphold a key patent on Pfizer's top drug. |
The Motley Fool
April 30, 2008
Brian Lawler |
The Start of a New Endo The drugmaker marks its first quarter under new management. |
The Motley Fool
April 30, 2008
Brian Lawler |
Idenix Aims for a Comeback This drugmaker may be down, but it's not yet out. |
The Motley Fool
April 30, 2008
Brian Lawler |
Alexza Advances 2 More Drugs The pharmaceutical company's compounds keep zipping through clinical trials. |
The Motley Fool
April 30, 2008
Brian Lawler |
A Dominating Danish Drugmaker Novo Nordisk turns in solid first-quarter financial numbers. |
The Motley Fool
April 30, 2008
Brian Lawler |
A Tale of 2 DNA Drugs More trouble for Genentech's No. 2 product, the systemic lupus treatment Rituxan. |
The Motley Fool
April 30, 2008
Brian Orelli |
Medco's Far-From-Generic Quarter Pharmacy benefit manager Medco Health Solutions benefits from new generic drugs. |
The Motley Fool
April 30, 2008
Brian Lawler |
BioMarin's Bodacious Earnings BioMarin raises revenue guidance for all of its marketed drugs, thanks to strong sales so far in 2008. |
The Motley Fool
April 29, 2008
Brian Lawler |
Sciele's Blue-Moon Buyback The specialty pharmaceutical surprisingly renews its share repurchase plan. |
The Motley Fool
April 29, 2008
Brian Orelli |
Will These Drugs Get FDA Approval? Discovery Laboratories and Adolor are waiting FDA decisions on their drugs next month. |
The Motley Fool
April 29, 2008
Brian Lawler |
Medarex Takes Another Hit Its lead cancer-fighting drug suffers a regulatory delay. |
The Motley Fool
April 29, 2008
Brian Lawler |
So Pharmasset, So Good Early data hints at a promising hepatitis C treatment. |
The Motley Fool
April 29, 2008
Brian Orelli |
Merck's Recovery Flushed Down Merck's best hope at recovery fails approval by the FDA. |
The Motley Fool
April 28, 2008
Brian Lawler |
Flamel Inches Forward New sales data arrives for one lead drug, new promising data for another. |
The Motley Fool
April 28, 2008
Brian Lawler |
ImClone on the Upswing The pharmaceutical's latest results show continuing improvement. |
The Motley Fool
April 28, 2008
Brian Orelli |
FDA Moves Isis' Finish Line The FDA tells drugmaker Isis it must complete cancer tests before submitting its marketing application. |
The Motley Fool
April 28, 2008
Brian Lawler |
Amgen's Anemic Earnings Drug troubles and potential label changes continue to hurt Amgen's earnings. |
The Motley Fool
April 28, 2008
Brian Lawler |
Glaxo Getting By Weakening currency barely redeems the pharmaceutical's Q1 numbers. |
The Motley Fool
April 28, 2008
Brian Lawler |
CV Therapeutics Feels the Love CV Therapeutics announces its second regulatory thumbs-up this month, after its lead drug Ranexa was essentially approved in the European Union. |
The Motley Fool
April 28, 2008
Brian Lawler |
Bristol-Myers' Comeback Continues The pharmaceutical's first quarter brings more robust results. |
Chemistry World
April 25, 2008
James Mitchell Crow |
Drug Costs Cut on World Malaria Day Swiss pharmaceuticals firm Novartis has announced it will reduce by one fifth the price it charges governments and NGOs for artemisinin-based antimalarial Coartem. |
Chemistry World
April 24, 2008
James Mitchell Crow |
FDA takes tough line on biologic drug The US Food and Drug Administration has rejected an application from biotechnology firm Genzyme to make its already-approved, protein-based drug Myozyme in larger batches. |
Fast Company
May 2008
Greg Lindsay |
Medical Leave Your next heart surgery could well be in Bangkok -- but don't worry, it'll be "in network." How your health care is taking wing ... |
Chemistry World
April 17, 2008
Nuala Mora |
World's first therapeutic cancer vaccine approved In move that will be a fillip to cancer vaccine developers, US biotech Antigenics has won Russian approval to market Oncophage to treat kidney cancer. |
Chemistry World
April 9, 2008
Richard Van Noorden |
The shortest recipe for Tamiflu US chemists have published the shortest synthesis to date of oseltamivir (Tamiflu), the anti-influenza drug which is also used to treat bird flu. |
Chemistry World
April 14, 2008
Ananyo Bhattacharya |
Psychiatric Drug Ads 'Frequently Misleading' Advertisements for psychiatric drugs - including many top-selling antidepressants - often make claims that are either misleading or impossible to verify, according to a new US study. |
Reason
April 2008
Ronald Bailey |
Medical Speech As a 1997 law expires, the FDA is mulling a plan allowing companies to disseminate unabridged reprints of "truthful and non-misleading" medical journal articles describing "off-label" uses of approved medications to physicians. |
Chemistry World
April 9, 2008
Mark Peplow |
vCJD filter for blood could be in use 'by summer' ProMetic's prion filter, attached to a blood pack, is being marketed by French medical equipment company MacoPharma to clean blood of the proteins responsible for variant Creutzfeldt-Jakob disease (vCJD). |
Managed Care
March 2008
Martin Sipkoff |
The Epilepsy Battle in the War Between Brands and Generics Brand-name manufacturers and many neurologists see danger in generic substitution, but the FDA insists that the practice is safe |
Managed Care
March 2008
Lola Butcher |
Health Plans Come Together for Better Outcomes Research Companies that participate in large research cooperatives such as the HMO Research Network are helping the whole medical system |
Managed Care
March 2008
Kathryn J. Alexander |
Health Plans Embrace Retail Clinics Convenient care clinics, as they like to be called, are spreading quickly because members and plans like them |
Managed Care
March 2008
Neil Versel |
Health 2.0: Will Its Promise Be Realized? Advocates say new health care websites will transform health care; detractors warn against overestimating the potential |
Managed Care
March 2008
John Carroll |
Should Plans Pay Physicians To Switch Patients to Generics? The AMA calls it a kickback, but the industry sees it as just good practice to give doctors an incentive to get patients on equivalent generics |
Managed Care
March 2008 |
Proposed 2009 HEDIS Measures Address Immunization, Obesity Rates The National Committee for Quality Assurance wants to expand what the committee's Healthcare Effectiveness Data and Information Set (HEDIS) measures look at in 2009. |
Managed Care
March 2008 |
Drug Caps Lower Spending, but .... These policies tend to make consumers shoulder some of the cost of prescriptions and the cost could be a barrier to medication adherence. |
Managed Care
March 2008 |
New Drug Abuse Codes Adopted The American Medical Association says that new CPT codes it developed should make it easier for health plans to determine whether doctors have screened for drug abuse. |
Managed Care
March 2008
Tony Berberabe |
Headlines On Deadline ... The Cleveland Clinic has joined with the Internet giant Google to test a secure exchange of patient medical record data involving prescriptions, conditions, and allergies. |
Managed Care
March 2008
Martin Sipkoff |
PBMs' Rebate Income Threatened By Lawsuits and Move to Generics A recent court settlement may affect the way the PBM industry makes profits, but could it also lead to higher drug costs? |
Managed Care
March 2008 |
CMS Hybrid Payment System Shows Promise Combining Medicare fee-for-service payments with new incentive programs could help physician groups save money for Medicare and reach quality-of-care targets. |
Managed Care
March 2008 |
PDP Drug Restrictions Block Comparison Shopping A review of 169 commonly used drugs covered by Medicare Prescription Drug Plans (PDPs) reveals that only 4 of the 10 largest plans by enrollment have all of those 169 drugs on formulary. |
Managed Care
March 2008 |
Specialty Drug Spending to Double by 2010 Additional indications for existing products, rather than new products, account for the bulk of increased specialty drug use. |
Chemistry World
April 3, 2008
Rebecca Trager |
GSK Challenge to US Patent Rules Successful A US district court has said that the US patent office cannot introduce new rules that drug firms argued were a threat to innovation. |
| There are 5081 old articles available for this category. |
